Oral mucositis in patients treated with chemotherapy agents that target the epidermal growth factor receptor (EGFR) or human EGFR2 (HER2)
A) Grade 1 mucositis with panitumumab (monoclonal antibody targeting
EGFR).
B) Mucositis induced by afatinib (pan-HER tyrosine kinase inhibitor).
C) Mucositis involving the labial mucosa induced by erlotinib in monotherapy
(antiEGFR).
D) Diffuse radio-induced mucositis affecting the keratinized mucosa (dorsum of
the tongue).
E) High-grade ≥3 mucositis induced by the association of head and neck radiotherapy
and cetuximab.
F) Mucositis induced by cetuximab and chemotherapy (carboplatin and 5FU) in
combination.
Reprinted by permission from Springer: Supportive Care in Cancer. Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017; 25:1713. Copyright © 2017.
https://www.springer.com/journal/520.
